Show simple item record

dc.contributor.authorZozaya, Néboa
dc.contributor.authorMartínez-Galdeano, Lucía
dc.contributor.authorAlcala, Bleric
dc.contributor.authorArmario-Hita, Jose Carlos
dc.contributor.authorCarmona, Concepción
dc.contributor.authorCarrascosa, Jose Manuel
dc.contributor.authorHerranz, Pedro
dc.contributor.authorLamas, María Jesús
dc.contributor.authorTrapero-Bertran, Marta
dc.contributor.authorHidalgo-Vega, Álvaro
dc.date.accessioned2021-06-28T16:04:01Z
dc.date.available2021-06-28T16:04:01Z
dc.date.issued2018
dc.identifier.citationZozaya, Néboa; Martínez-Galdeano, Lucía; Alcala, Bleric [et al.]. Determining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysis. BioDrugs, 2018, 32, p. 281-291. Disponible en: <https://link.springer.com/article/10.1007/s40259-018-0284-3>. Fecha de acceso: 28 jun. 2021. DOI: 10.1007/s40259-018-0284-3ca
dc.identifier.issn1173-8804ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2659
dc.description.abstractBackground and Objective: Multi-criteria decision analysis (MCDA) is a tool that systematically considers multiple factors relevant to health decision-making. The aim of this study was to use an MCDA to assess the value of dupilumab for severe atopic dermatitis compared with secukinumab for moderate to severe plaque psoriasis in Spain. Method: Following the EVIDEM (Evidence and Value: Impact on DEcision Making) methodology, the estimated value of both interventions was obtained by means of an additive linear model that combined the individual weighting (between 1 and 5) of each criterion with the individual scoring of each intervention in each criterion. Dupilumab was evaluated against placebo, while secukinumab was evaluated against placebo, etanercept and ustekinumab. A retest was performed to assess the reproducibility of weights, scores and value estimates. Results: The overall MCDA value estimate for dupilumab versus placebo was 0.51 ± 0.14. This value was higher than those obtained for secukinumab: 0.48 ± 0.15 versus placebo, 0.45 ± 0.15 versus etanercept and 0.39 ± 0.18 versus ustekinumab. The highest-value contribution was reported by the patients’ group, followed by the clinical professionals and the decision makers. A fundamental element that explained the difference in the scoring between pathologies was the availability of therapeutic alternatives. The retest confirmed the consistency and replicability of the analysis. Conclusions: Under this methodology, and assuming similar economic costs per patient for both treatments, the results indicated that the overall value estimated of dupilumab for severe atopic dermatitis was similar to, or slightly higher than, that of secukinumab for moderate to severe plaque psoriasis.en
dc.format.extent11ca
dc.language.isoengca
dc.publisherSpringer Natureca
dc.relation.ispartofBioDrugsca
dc.relation.ispartofseries32;
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.en
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherMedicinesca
dc.subject.otherFàrmacsca
dc.subject.otherMalalties inflamatòriesca
dc.subject.otherPellca
dc.subject.otherFàrmacs biològicsca
dc.subject.otherMedicinases
dc.subject.otherFármacoses
dc.subject.otherEnfermedades inflamatoriases
dc.subject.otherPieles
dc.subject.otherFármacos biológicoses
dc.subject.otherMedicineses
dc.subject.otherDrugsen
dc.subject.otherInflammatory diseasesen
dc.subject.otherPellen
dc.subject.otherBiological drugsen
dc.titleDetermining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysisen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.5ca
dc.identifier.doihttps://dx.doi.org/10.1007/s40259-018-0284-3ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/